ClinicalTrials.gg
TerminatedNCT06342960Updated Aug 31, 2026

KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

A Phase 1/2 interventional study of KYV-101 anti-CD19 CAR-T cell therapy and Standard lymphodepletion regimen in Lupus Nephritis, Lupus Nephritis - WHO Class III and Lupus Nephritis - WHO Class IV, sponsored by Kyverna Therapeutics. Terminated at 6 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Kyverna Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Study discontinued due to sponsor decision.

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Dec 2022, registered Mar 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Lupus Nephritis with a site in Germany — 4 open to participants now, 9 under way, 3 of them phase 3. Lupus Nephritis · Germany.

Enrollment
28th of 29
2 · median 100
Started
2022
with 5 others
Phase 1/2
3 of 32
none open now
Registered
26th of 32
by date

Among the 32 studies in Lupus Nephritis with a site in Germany, this one is the 28th largest by enrollment of the 29 interventional ones that give a count, is one of 6 that started in 2022, is one of 3 in phase 1/2, and was the 26th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

4 of the 32 studies in Lupus Nephritis with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Lupus Nephritis with a site in Germany, or all of them as a file.
02

Study summary

A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis

Read the detailed description

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by a wide spectrum of organ involvement and disease severity. Renal involvement (categorized as lupus nephritis [LN]) may occur in approximately 50% of SLE patients and is marked by proteinuria, microscopic hematuria, and varying degrees of renal insufficiency. B cells play a central role in the pathogenesis of SLE and LN, with autoantibodies developing as an early finding, and local, tissue resident B cells producing pathogenic autoantibodies and driving inflammation and tissue damage over time. CD19-targeted chimeric antigen receptor (CAR) T cells harness the ability of cytotoxic T cells to directly and specifically lyse target cells to effectively deplete B cells in the circulation and in lymphoid and potentially non-lymphoid tissues. KYV-101, a fully human anti-CD19 CAR T-cell therapy, will be investigated in adult subjects with refractory lupus nephritis.

03

Conditions studied

  • Lupus Nephritis
  • Lupus Nephritis - WHO Class III
  • Lupus Nephritis - WHO Class IV

Keywords

  • KYV-101
  • glomerulonephritis
  • autoimmune disease
  • anti-CD19 CAR-T therapy
  • cellular therapy
  • SLE
  • Systemic lupus erythematosus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Clinical diagnosis of SLE according to 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria
  3. -proven proliferative LN Class III or IV according to 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria
  4. Positive anti-nuclear antibody (ANA) (titer ≥1:80 ), anti-dsDNA (≥30 IU/mL on enzyme-linked immunosorbent assay [ELISA]), or anti-Smith at screening or by documented medical history
  5. Up to date on recommended vaccinations, including against coronavirus disease 2019/ severe acute respiratory syndrome coronavirus 2 (Covid-19/SARS-Cov-2), per Centers for Disease Control and Prevention (CDC) or institutional guidelines for immune compromised individuals

Exclusion criteria

Exclusion Criteria:

  1. Rapidly progressive glomerulonephritis; history of or currently active severe central nervous system (CNS) lupus, including cerebritis, cerebrovascular accident, and seizures
  2. Prior treatment with cellular therapy (CAR-T) or gene therapy product directed at any target
  3. History of or autologous stem cell transplant
  4. Evidence of active or infection
  5. Positive serology for
  6. Primary immunodeficiency
  7. History of splenectomy
  8. History of stroke, seizure, dementia, Parkinson's disease, coordination movement disorder, cerebellar diseases, psychosis, paresis, aphasia, and any other neurologic disorder investigator considers would increase the risk for the subject.
  9. Impaired cardiac function or cardiac disease
  10. Previous or concurrent with the following exceptions:

    1. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to screening)
    2. In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to screening
    3. A primary malignancy which has been completely resected, or treated, and is in complete remission for at least 5 years prior to screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 1)

    Dosing with KYV-101 CAR T cells

    Biological: KYV-101 anti-CD19 CAR-T cell therapy · Drug: Standard lymphodepletion regimen

  • Experimental
    KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 2)

    Recommended Phase 2 Dose

    Biological: KYV-101 anti-CD19 CAR-T cell therapy · Drug: Standard lymphodepletion regimen

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence adverse events (AEs) and laboratory abnormalities (Phase 1 and Phase 2)

    Time frame: Up to 2 years

  2. Frequency of dose limiting toxicities (Phase 1)

    Time frame: Up to 2 years

Secondary outcomes

  1. To characterize the pharmacokinetics (PK) (Phase 1 and 2)

    Levels of KYV-101 CAR-positive T cells in the blood

    Time frame: Up to 2 years

  2. To characterize the pharmacokinetics (PK) (Phase 1 and 2)

    Levels of KYV-101 CAR Transgene

    Time frame: Up to 2 years

  3. To characterize the pharmacodynamics (PD) (Phase 1 and 2)

    Levels of B cells in the blood

    Time frame: Up to 2 years

  4. To characterize the pharmacodynamics (PD) (Phase 1 and 2)

    Levels of systemic cytokine concentrations in serum

    Time frame: Up to 2 months

  5. To evaluate disease related biomarkers (Phase 1 and 2)

    Levels of anti-double stranded DNA (anti-dsDNA) in serum

    Time frame: Up to 2 years

  6. To evaluate disease related biomarkers (Phase 1 and 2)

    Levels of complement C3, C4 in serum

    Time frame: Up to 2 years

  7. To evaluate efficacy of KYV-101 (Phase 1 and 2)

    Complete renal response rates (CRR)

    Time frame: 12, 24, and 52 weeks

  8. To evaluate efficacy of KYV-101 (Phase 1 and 2)

    Time to Complete renal response (CRR)

    Time frame: Up to 2 years

  9. To evaluate efficacy of KYV-101 (Phase 1 and 2)

    Time from first achieved Complete renal response (CRR) to disease worsening or end of study

    Time frame: Up to 2 years

  10. To evaluate the immunogenicity (humoral response) of KYV-101 (Phase 1 and 2)

    Percentage of participants who develop anti-KYV-101 antibodies by immunoassays

    Time frame: Up to 2 years

  11. To access Patient Related Outcome (PRO) after infusion of KYV-101 (Phase 1 and 2)

    Change from baseline in 36-Item Short Form Survey (SF-36)

    Time frame: Up to 2 years

  12. To access Patient Related Outcome (PRO) after infusion of KYV-101 (Phase 1 and 2)

    Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F)

    Time frame: Up to 2 years

  13. To access Patient Related Outcome (PRO) after infusion of KYV-101 (Phase 1 and 2)

    Change from baseline in Lupus Quality of Life (Qol) Questionnaire

    Time frame: Up to 2 years

  14. To access Patient Related Outcome (PRO) after infusion of KYV-101 (Phase 1 and 2)

    Change from baseline in Work Productivity and Activity Impairment (WPAI)

    Time frame: Up to 2 years

  15. To define the recommended Phase 2 dose (Phase 1)

    Time frame: Up to 2 years

07

Study locations

6 sites
  • Charite- Universitätsklinikum Berlin
    Berlin, Germany
  • Universitätsklinikum Carl Gustav Carus Dresden
    Dresden, Germany
  • Universitätsklinikum Düsseldorf
    Düsseldorf, Germany
  • Universitätsklinikum Erlangen
    Erlangen, Germany
  • Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP
    Frankfurt, Germany
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, Germany
08

References and documents

Publications

  • Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, Roschewski M, Dean R, Cachau R, Youkharibache P, Patel R, Hansen B, Stroncek DF, Rosenberg SA, Gress RE, Kochenderfer JN. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020 Feb;26(2):270-280. doi: 10.1038/s41591-019-0737-3. Epub 2020 Jan 20. PubMed 31959992 ↗
  • Mackensen A, Muller F, Mougiakakos D, Boltz S, Wilhelm A, Aigner M, Volkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, Rosler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Kronke G, Schett G. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022 Oct;28(10):2124-2132. doi: 10.1038/s41591-022-02017-5. Epub 2022 Sep 15. PubMed 36109639 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Dec 2025, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2024
First posted
Apr 2, 2024
StartActual
Dec 1, 2022
Primary completionActual
Dec 22, 2025
CompletionActual
Dec 22, 2025
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06342960
Lead sponsor
Kyverna Therapeutics
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Dec 1, 2022
Primary completion
Dec 22, 2025
Completion
Dec 22, 2025
Last update
Aug 31, 2026

Study contacts

MD
study director · Kyverna Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mivocabtagene autoleucel

Start the discussion